Edition:
United Kingdom

Basilea Pharmaceutica AG (BSLN.S)

BSLN.S on Swiss Exchange

43.72CHF
4:31pm BST
Change (% chg)

CHF1.16 (+2.73%)
Prev Close
CHF42.56
Open
CHF42.84
Day's High
CHF43.88
Day's Low
CHF42.62
Volume
73,409
Avg. Vol
51,232
52-wk High
CHF73.95
52-wk Low
CHF38.60

About

Basilea Pharmaceutica AG is a Switzerland-based company engaged in the research, development and commercialization of pharmaceutical products. The Company focuses on pharmaceutical products in the therapeutic areas of bacterial infections, fungal infections and oncology. The Company has a range of drugs to treat drug-resistant... (more)

Overall

Beta: 1.30
Market Cap(Mil.): CHF505.59
Shares Outstanding(Mil.): 11.88
Dividend: --
Yield (%): --

Financials

  BSLN.S Industry Sector
P/E (TTM): -- 110.59 62.94
EPS (TTM): -2.89 -- --
ROI: -12.88 8.01 11.75
ROE: -- 8.19 12.58

BRIEF-Basilea Pharmaceutica FY Net Loss Widens To CHF 31.4 Million

* BASILEA REPORTS STRONG REVENUE GROWTH AND SIGNIFICANT PIPELINE PROGRESS FOR FULL-YEAR 2018

19 Feb 2019

Swiss stocks - Factors to watch on Feb. 8

ZURICH/BERLIN, Feb 8 The Swiss blue-chip SMI was seen opening 0.2 percent lower at 9.018 points on Friday, according to premarket indications by bank Julius Baer .

08 Feb 2019

BRIEF-Basilea Pharmaceutica: Strong European Cresemba Sales Trigger $5 Mln Milestone Payment

* STRONG EUROPEAN CRESEMBA® (ISAVUCONAZOLE) SALES TRIGGER USD 5 MILLION MILESTONE PAYMENT TO BASILEA FROM PFIZER

08 Feb 2019

BRIEF-Basilea Says Adesh Kaul Appointed CFO

* BASILEA ANNOUNCES CHANGE IN THE MANAGEMENT COMMITTEE - ADESH KAUL APPOINTED CFO

07 Feb 2019

BRIEF-Basilea Announces Collaboration To Study Derazantinib And Atezolizumab In Urothelial Cancer

* BASILEA ANNOUNCES COLLABORATION TO STUDY DERAZANTINIB AND ATEZOLIZUMAB (TECENTRIQ®) IN UROTHELIAL CANCER

24 Jan 2019

BRIEF-Basilea Announces Collaboration To Study Derazantinib And Atezolizumab In Urothelial Cancer

* BASILEA ANNOUNCES COLLABORATION TO STUDY DERAZANTINIB AND ATEZOLIZUMAB (TECENTRIQ®) IN UROTHELIAL CANCER

24 Jan 2019

BRIEF-Basilea: Positive Interim Results From Registrational Phase 2 Study With Derazantinib

* BASILEA REPORTS POSITIVE INTERIM RESULTS FROM REGISTRATIONAL PHASE 2 STUDY WITH ONCOLOGY DRUG CANDIDATE DERAZANTINIB IN INTRAHEPATIC CHOLANGIOCARCINOMA (ICCA)

09 Jan 2019

BRIEF-Basilea Preliminary FY Revenue At CHF 133 Mln

* BASILEA REPORTS STRONG, HIGHER THAN EXPECTED PRELIMINARY REVENUE OF CHF 133 MILLION FOR FINANCIAL YEAR 2018

07 Jan 2019

BRIEF-Basilea Pharmaceutica: CHF 10 Million Milestone Payment For Cresemba Sales

* CONTINUED STRONG CRESEMBA® (ISAVUCONAZOLE) U.S. SALES PERFORMANCE BY ASTELLAS PHARMA INC. TRIGGERS CHF 10 MILLION MILESTONE PAYMENT TO BASILEA

10 Dec 2018

BRIEF-Basilea Presents Preclinical Data On Anticancer Drug Candidate Bal101553 At Eortc-Nci-Aacr Symposium

* BASILEA PRESENTS PRECLINICAL DATA ON ITS ANTICANCER DRUG CANDIDATE BAL101553 AT EORTC-NCI-AACR SYMPOSIUM Source text for Eikon: Further company coverage: (Gdynia Newsroom)

14 Nov 2018

Earnings vs. Estimates